December 11, 2014
Otsuka Pharmaceutical and its Danish partner H. Lundbeck A/S said on December 11 that their investigational antipsychotic agent brexpiprazole significantly improved psychiatric symptoms in patients with schizophrenia compared to placebo in two US PIII clinical studies. One of the studies...read more